Detection of EGFR mutations in plasma cfDNA and CTCs of NSCLC patients using Crystal Digital PCR

Liquid biopsy is a useful tool during longitudinal monitoring of NSCLC patients but requires highly sensitive and reliable technologies for accurate detection of genomic alterations. Circulating tumor DNA (ctDNA) analysis has clinical utility in EGFR mutant NSCLC, while Circulating tumor cells (CTCs) consist a unique source of information at the cellular level. Digital PCR (dPCR) is a valuable tool for accurate and valid analysis of gene mutations in liquid biopsy analysis. The scope of the present study was to evaluate the presence and estimate mutation allele frequencies (MAFs) of EGFR mutations in plasma cfDNA and corresponding CTC-derived gDNA using Crystal Digital PCR™, in a group of EGFR mutant NSCLC patients under osimertinib therapy at two time points (before treatment initiation and at progression of disease).